News

Gilead Sciences (NasdaqGS:GILD) Gains FDA Approval For Yeztugo As PrEP HIV Option
Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...
Pharmaceutical Technology on MSN1d
Gilead Sciences’ Yeztugo receives approval from US FDA for HIV
The FDA has approved Gilead Sciences' injectable product, Yeztugo (lenacapavir), as a pre-exposure prophylaxis (PrEP) against ...
BioPharma Dive2d
FDA approves twice-yearly shot of Gilead drug for HIV prevention
The clearance ushers in a closely-watched launch for Gilead, which aims to show a long-acting injection can upend a market ...
PharmExec1d
FDA Approves Gilead’s Yeztugo as First Twice-Yearly Injection for HIV Pre-Exposure Prophylaxis
Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® ...
Stocktwits on MSN1d
Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV Prevention
Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...
STAT1d
Gilead’s CEO on the approval of a powerful new drug to prevent HIV
Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...
Daily Graphic15h
FDA approves powerful HIV prevention drug: What to know about Yeztugo
The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported ...
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time.
The Food and Drug Administration approved a twice-yearly shot that prevented HIV infections in 99.9% of the people who ...
PMLive1d
Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval
Gilead Sciences’ twice-yearly injectable pre-exposure prophylaxis (PrEP) drug has been approved by the US Food and Drug ...
Fierce Pharma2d
FDA signs off on Gilead's landmark long-acting PrEP med, signaling new era in HIV prevention
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...